Beigene, Ltd. (NASDAQ:ONC) Insider Titus B. Ball Sells 134 Shares

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Titus B. Ball sold 134 shares of Beigene stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $258.36, for a total value of $34,620.24. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Beigene Trading Down 2.5%

ONC traded down $6.90 on Friday, hitting $269.63. 391,727 shares of the company were exchanged, compared to its average volume of 451,056. Beigene, Ltd. has a twelve month low of $141.31 and a twelve month high of $287.88. The stock has a market capitalization of $29.52 billion, a P/E ratio of -32.72, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $241.38.

Beigene (NASDAQ:ONC - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. Equities analysts expect that Beigene, Ltd. will post -5.82 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ONC. JPMorgan Chase & Co. lifted their price objective on Beigene from $311.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, April 21st. Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and lifted their target price for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Royal Bank of Canada reduced their target price on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. Guggenheim lifted their target price on Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded Beigene from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $319.00.

Beigene Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.